Compare AZO & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AZO | ALNY |
|---|---|---|
| Founded | 1979 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto & Home Supply Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.4B | 52.9B |
| IPO Year | 1991 | 2004 |
| Metric | AZO | ALNY |
|---|---|---|
| Price | $3,662.73 | $322.44 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 20 | 27 |
| Target Price | ★ $4,283.21 | $474.42 |
| AVG Volume (30 Days) | 173.0K | ★ 1.7M |
| Earning Date | 03-03-2026 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 143.45 | 0.33 |
| Revenue | ★ $19,287,706,000.00 | $3,210,070,000.00 |
| Revenue This Year | $9.63 | $70.40 |
| Revenue Next Year | $7.43 | $44.32 |
| P/E Ratio | ★ $25.33 | $970.12 |
| Revenue Growth | 3.81 | ★ 53.24 |
| 52 Week Low | $3,210.72 | $205.87 |
| 52 Week High | $4,388.11 | $495.55 |
| Indicator | AZO | ALNY |
|---|---|---|
| Relative Strength Index (RSI) | 53.42 | 28.83 |
| Support Level | $3,577.83 | $333.00 |
| Resistance Level | $3,787.34 | $355.49 |
| Average True Range (ATR) | 95.45 | 11.67 |
| MACD | -6.76 | -1.38 |
| Stochastic Oscillator | 34.73 | 7.78 |
AutoZone operates as a leading retailer of aftermarket automotive parts in the United States. The firm operates 6,666 stores domestically, serving the do-it-yourself and commercial (do-it-for-me) end markets. Through its vast store footprint and distribution network, AutoZone manages a wide array of stock-keeping units applicable to numerous vehicle makes and models, providing its consumers with ample product availability. The firm drives traffic by providing superior and convenient customer service as AutoZone's team of knowledgeable staff assists consumers with diagnosing a vehicle's problem, selecting the necessary part for replacement, and occasionally, installation. The company also operates internationally, with 895 stores in Mexico and 149 in Brazil.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.